Cullinan Oncology, Inc., (Nasdaq: CGEM) (“Cullinan Oncology”) a
biopharmaceutical company focused on modality-agnostic targeted
oncology therapies, today announced that posters of preclinical
data highlighting the therapeutic potential of two assets, CLN-619
and CLN-617, will be presented at the 2023 American Association for
Cancer Research (AACR) Annual Meeting taking place in Orlando,
Florida, April 14-17, 2023.
Details of the Cullinan Oncology posters at
AACR are as follows:
Poster Title: The Structural Basis
for Inhibition of MICA Shedding and Anti-Tumor Activity of the
Monoclonal Anti-MICA/B Antibody, CLN-619Session:
Therapeutic Antibodies 2Session Date/Time: Monday,
April 17, 2023, 1:30 pm – 5 pm ETLocation: Poster
Section 23Abstract Number: 2943Poster
Board Number: 21Authors: Kerry A. Whalen,
Naveen K. Mehta, Kristan Meetze, Jennifer S. Michaelson, Patrick A.
Baeuerle
Poster Title: CLN-617 is a
First-in-Class Fusion Protein That Retains IL-2 and IL-12 in the
Injected Tumor and Potently Triggers Systemic Anti-Tumor
ImmunitySession: Immunomodulatory Agents and
Interventions 2Session Date/Time: Monday, April
17, 2023, 9 am – 12:30 pm ETLocation: Poster
Section 24Abstract Number: 1839Poster
Board Number: 11Authors: Naveen K. Mehta,
Kavya Rakhra, Kristan Meetze, K. Dane Wittrup, Jennifer S.
Michaelson, Patrick A. Baeuerle
“We are proud to present data at this year’s AACR
conference for two programs in our diverse and robust pipeline,
CLN-619 which is a MICA/B directed IgG1 antibody and CLN-617, an
IL-2 and IL-12 cytokine therapy,” said Dr. Patrick Baeuerle, Chief
Scientific Officer, Cullinan Oncology. “While distinct programs,
each has the potential to be a first- and/or best-in-class therapy
across a broad range of solid tumor types. We are excited to
present more data on these two programs in poster presentations at
AACR 2023 and highlight the strides we are making toward creating
new standards of care for patients with cancer.”
The posters will expand on preclinical research
that has been conducted for both molecules.
About CLN-619CLN-619 is a
potential first-in-class humanized IgG1 monoclonal antibody that
binds to the stress induced ligands, MICA and MICB, which are
expressed on a wide variety of hematological and solid tumors.
Engagement of MICA/B by the activating receptor NKG2D, present on
both cytotoxic innate and adaptive immune cells, results in target
cell lysis. However, tumor cells can shed MICA/B via proteases they
release into the tumor microenvironment, resulting in evasion of
immune-mediated destruction. CLN-619 functions by restoring MICA/B
expression on the surface of tumor cells, enhancing the interaction
between MICA and NKG2D, and inducing antibody-dependent cellular
toxicity (ADCC), together promoting anti-tumor activity via
NKG2D-expressing NK and T cells. CLN-619 is being studied in an
ongoing Phase 1 clinical trial both as a monotherapy and in
combination with pembrolizumab. The study design allows dose level
extensions as well as expansion in tumor-specific cohorts. The
trial was initiated in December 2021, and initial clinical data is
anticipated in mid-2023.
About CLN-617CLN-617 is a
potential first-in-class cytokine therapy uniquely combining two
potent and synergistic antitumor cytokines, IL-2 and IL-12, in a
single molecule. The molecule is intended for intratumoral
injection and employs collagen-binding and size-enhancing domains
designed to retain the CLN-617 molecule inside the tumor and
thereby enhance efficacy and reduce toxicity. While CLN-617 is
injected and retained locally in the tumor, it directs a broad
immune response that may help eradicate not only the injected
tumor, but also attack distant tumor sites, as observed in
preclinical studies. Pre-clinical studies have also demonstrated
the potential for enhanced efficacy when CLN-617 is combined with
checkpoint inhibitor therapy. Cullinan plans to evaluate CLN-617 in
a phase 1 clinical trial in patients with advanced solid
tumors.
About Cullinan
Oncology Cullinan
Oncology, Inc. (Nasdaq: CGEM) is a biopharmaceutical company
dedicated to creating new standards of care for patients with
cancer. We innovate without borders to find the most promising
clinic-ready cancer therapies, whether from our own discovery
efforts or through exceptional engagement with our academic and
industry partners. Anchored in a deep understanding of
immuno-oncology and translational cancer medicine, we leverage our
scientific excellence in small molecules and biologics to create
differentiated ideas, identify unique targets, and select the
optimal modality to develop transformative therapeutics across
cancer indications. Powered by our novel research model, we push
conventional boundaries from candidate selection to cancer
therapeutic, applying rigorous early experimentation to fast-track
only the most promising assets to the clinic and ultimately
commercialization. As a result, our diversified pipeline is
strategically built with assets that activate the immune system or
inhibit key oncogenic drivers across a wide range of modalities,
each with the potential to be the best or first in their class.
Our people possess deep scientific expertise, seek
innovation openly, and exercise creativity and urgency to deliver
on our promise to bring new therapeutic solutions to patients with
cancer. Learn more about our Company
at www.cullinanoncology.com, and follow us
on LinkedIn and Twitter.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
These forward-looking statements include, but are not limited to,
express or implied statements regarding Cullinan’s beliefs and
expectations regarding the potential benefits and therapeutic
potential of CLN-619 and CLN-617; our clinical development plans
and timelines; our plans regarding future data presentations and
other statements that are not historical facts. The words
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“hope,” “intend,” “may,” “plan,” “potential,” “predict,” “project,”
“target,” “should,” “would,” and similar expressions are intended
to identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Any forward-looking statements in this press
release are based on management's current expectations and beliefs
of future events and are subject to known and unknown risks and
uncertainties that may cause our actual results, performance or
achievements to be materially different from any expressed or
implied by the forward-looking statements. These risks include, but
are not limited to, the following: uncertainty regarding the timing
and results of regulatory submissions; success of our clinical
trials and preclinical studies; risks related to our ability to
protect and maintain our intellectual property position; risks
related to manufacturing, supply, and distribution of our product
candidates; risks related to the impact of COVID-19 affecting
countries or regions in which we have operations or do business,
including potential negative impacts on our employees, customers,
supply chain and production as well as global economies and
financial markets; the risk that any one or more of our product
candidates, including those that are co-developed, will not be
successfully developed and commercialized; the risk that the
results of preclinical studies or clinical studies will not be
predictive of future results in connection with future studies; and
success of any collaboration, partnership, license or similar
agreements. These and other important risks and uncertainties
discussed in our filings with the Securities and Exchange
Commission, including under the caption “Risk Factors” in our most
recent Annual Report on Form 10-K and subsequent filings with the
SEC, could cause actual results to differ materially from those
indicated by the forward-looking statements made in this press
release. While we may elect to update such forward-looking
statements at some point in the future, we disclaim any obligation
to do so, even if subsequent events cause our views to change,
except to the extent required by law. These forward-looking
statements should not be relied upon as representing our views as
of any date subsequent to the date of this press release. Moreover,
except as required by law, neither Cullinan nor any other person
assumes responsibility for the accuracy and completeness of the
forward-looking statements included in this press release. Any
forward-looking statement included in this press release speaks
only as of the date on which it was made.
Contacts:
InvestorsCullinan Oncology:Chad Messer+1
203.464.8900cmesser@cullinanoncology.com
Media Cullinan Oncology:Rose Weldon+1
215.801.7644rweldon@cullinanoncology.com
Cullinan Therapeutics (NASDAQ:CGEM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cullinan Therapeutics (NASDAQ:CGEM)
Historical Stock Chart
From Jul 2023 to Jul 2024